Hemoglobin News and Research

RSS

Georgia Tech hosts symposium to discuss sickle cell disease

Georgia Tech will host the Sickle Cell Disease Symposium bringing together researchers, policy experts and community advocates to discuss the latest research and strategies for future success in combating this complex and debilitating blood disorder. The symposium begins at Georgia Tech's Institute for Bioengineering and Bioscience on November 4 and concludes the evening of November 5.

4 Nov 2010

Positive preliminary data from Protalix's taliglucerase alfa switchover trial for Gaucher disease

Protalix BioTherapeutics, Inc., announced today positive preliminary data from the first 15 patients that completed the Company's nine month, worldwide, multi-center, open-label, switchover trial of taliglucerase alfa for the treatment of Gaucher disease under a protocol cleared by the U.S. Food and Drug Administration (FDA). The data indicate that patients can safely be switched to taliglucerase alfa from imiglucerase (Cerezyme®).

2 Nov 2010

Boehringer to present data of SOUND-C1 Phase Ib study for HCV treatment at AASLD Meeting

Boehringer Ingelheim announced results from a Phase Ib study, SOUND-C1, that showed the combination of two oral hepatitis C virus (HCV) compounds, the protease inhibitor BI 201335 and the polymerase inhibitor BI 207127, with ribavirin reduced viral load to the lower limit of quantifiable levels in HCV treatment-naïve patients.

1 Nov 2010

BioMedix receives ONC-ATCB 2011/2012 certification for TRAKnet Practice Management Software

BioMedix announced today that TRAKnet Practice Management Software 2.0 is 2011/2012 compliant and was certified as a Complete EHR on October 28th, 2010 by the Certification Commission for Health Information Technology (CCHIT®), an ONC-ATCB, in accordance with the applicable Eligible Provider certification criteria adopted by the Secretary of Health and Human Services.

30 Oct 2010

Nanomedicine Center for Nucleoprotein Machines receives $16.1 million NIH award

The Georgia Tech-led Nanomedicine Center for Nucleoprotein Machines has received an award of $16.1 million for five years as part of its renewal by the National Institutes of Health (NIH). The eight-institution research team plans to pursue development of a clinically viable gene correction technology for single-gene disorders and demonstrate the technology's efficacy with sickle cell disease.

29 Oct 2010

CHORI hosts 2nd annual international Advanced Workshop on Sickle Cell Disease

Children's Hospital & Research Center Oakland is hosting the 2nd annual international Advanced Workshop on Sickle Cell Disease October 28 and 29. This impressive conference will bring together hematologists from Pakistan, Saudi Arabia, Mexico, Venezuela, Brazil, and beyond, and the premier sickle cell experts from the United States for a dialogue on research, comprehensive care, and new treatments and therapies.

27 Oct 2010

Bristol-Myers Squibb 2010 third quarter U.S. net sales increases 4% to $3.1 billion

Bristol-Myers Squibb Company today reported results for the third quarter of 2010. Highlights in the quarter included: the presentation of new data on investigational compounds in the diabetes and cardiovascular disease franchises at major medical meetings; the completion of important regulatory milestones in the oncology, diabetes and immunoscience franchises; the acquisition of ZymoGenetics; and double-digit EPS growth. The company also confirmed guidance for 2010.

26 Oct 2010

High erythropoietin levels predict higher mortality

High erythropoietin levels in people over age 85 indicate a higher risk of death, according to a study published in CMAJ.

26 Oct 2010

Rockwell Medical announces design of Phase III development program for Soluble Ferric Pyrophosphate

Rockwell Medical, a fully-integrated biopharmaceutical company offering innovative products and services targeting end-stage renal disease (ESRD), chronic kidney disease (CKD), and iron-deficiency anemia, announced today the design of its Phase III development program for Soluble Ferric Pyrophosphate (SFP) as a continuous iron replacement therapeutic.

20 Oct 2010

New brush optrode improves optical scanning of brain activity

One of the main techniques for measuring and monitoring mental activity, called functional near infrared spectroscopy (fNIRS), can often be impaired because a person's hair gets in the way. But now, thanks to a team of researchers at the University of Texas at Dallas and the University of Texas at Arlington, a novel device called a "brush optrode" is providing increased sensitivity with fiber tips designed to thread through hair to enhance scalp contact.

20 Oct 2010

Nitric oxide inhalation reduces pain in sickle cell disease patients

Inhaling nitric oxide appears to safely and effectively reduce pain crises in adults with sickle cell disease, researchers report.

20 Oct 2010

Amgen to review study results of ESA in chronic renal failure patients with FDA and CRDAC

Amgen will review the results from TREAT (the Trial to Reduce Cardiovascular Events with Aranesp® Therapy) and will discuss how these results inform the appropriate use of erythropoiesis-stimulating agents (ESAs) for chronic renal failure (CRF) patients at today's meeting of the Food and Drug Administration's (FDA) Cardiovascular and Renal Drugs Advisory Committee (CRDAC).

19 Oct 2010

Peer partner program helps diabetic patients to manage their conditions

Phone calls with a peer facing the same self-management challenges helped diabetes patients manage their conditions and improved their blood sugar levels better than those who used traditional nurse care management services alone, according to research from the University of Michigan Health System.

19 Oct 2010

OrSense's NBM 200MP non-invasive Hb measurement system more accurate than invasive POC devices

OrSense Ltd., developer of monitors for non-invasive measurements of various blood parameters, presented in an oral presentation at the American Society of Anesthesiologists (ASA) annual meeting in San Diego, results showing that hemoglobin (Hb) measurements obtained by its NBM 200MP, a non-invasive Hb measurement system, showed accurate performance during hemorrhage conditions compared with invasive point of care (POC) devices.

18 Oct 2010

NBM 200 system accurately measures hemoglobin level

OrSense Ltd., developer of monitors for non-invasive measurements of various blood parameters, presented today at the AABB Annual Meeting & CTTXPO 2010, in Baltimore, Maryland, results showing that hemoglobin (Hb) measurements obtained by its NBM 200, a non-invasive Hb measurement system for anemia screening, showed accurate performance compared with invasive point of care (POC) devices.

11 Oct 2010

Pfizer announces tasocitinib Phase 2 data for plaque psoriasis

Pfizer Inc. today announced that data from a Phase 2 efficacy and safety study of tasocitinib the company's investigational oral JAK inhibitor, met its primary endpoint of a statistically significant greater proportion of patients achieving at least a 75 percent reduction from baseline in PASI (Psoriasis Area and Severity Index) at week 12 in individuals with chronic moderate to severe plaque psoriasis.

8 Oct 2010

Merck's boceprevir Phase III studies for HCV to be presented at 61st AASLD

Merck today announced that final results from two pivotal Phase III studies of boceprevir, its investigational oral hepatitis C protease inhibitor, will be presented in oral plenary sessions at the 61st Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), which is taking place from Oct. 29 through Nov. 2 in Boston. Results for boceprevir in response-guided therapy strategies, which evaluated treatment durations shorter than current standard therapy, will be presented during the meeting.

4 Oct 2010

NIH funds $1.5M for research into prediction of stroke risk in pediatric patients with sickle cell disease

A researcher from the biomedical engineering department operated by Georgia Tech and Emory University has received a $1.5 million NIH Director's New Innovator Award to support a project aimed at reducing the incidence of stroke in children with sickle cell disease. Manu Platt, an assistant professor in the Wallace H. Coulter Department of Biomedical Engineering, will use the National Institutes of Health (NIH) funding to develop models for identifying which children with the disease are at risk for stroke.

1 Oct 2010

sanofi-aventis announces top-line results from lixisenatide Phase III GETGOAL-L-ASIA trial for Type-2 Diabetes

Zealand Pharma A/S, the biopharmaceutical company dedicated to the discovery and development of innovative peptide-based drugs, is pleased to note that its partner, sanofi-aventis, has today announced positive top-line results of the Phase III GETGOAL-L-ASIA trial which assessed the efficacy and safety of lixisenatide, a once-daily GLP-1 receptor agonist discovered by Zealand Pharma, in combination with basal insulin.

30 Sep 2010

XOMA completes patient enrollment in XOMA 052 Phase 2a trial

XOMA Ltd., a leader in the discovery and development of therapeutic antibodies, announced that patient enrollment was recently completed for the company's Phase 2a trial of XOMA 052 in patients with Type 2 diabetes.

29 Sep 2010

Hemoglobin News and Research

Georgia Tech hosts symposium to discuss sickle cell disease

Positive preliminary data from Protalix's taliglucerase alfa switchover trial for Gaucher disease

Boehringer to present data of SOUND-C1 Phase Ib study for HCV treatment at AASLD Meeting

BioMedix receives ONC-ATCB 2011/2012 certification for TRAKnet Practice Management Software

Nanomedicine Center for Nucleoprotein Machines receives $16.1 million NIH award

CHORI hosts 2nd annual international Advanced Workshop on Sickle Cell Disease

Bristol-Myers Squibb 2010 third quarter U.S. net sales increases 4% to $3.1 billion

High erythropoietin levels predict higher mortality

Rockwell Medical announces design of Phase III development program for Soluble Ferric Pyrophosphate

New brush optrode improves optical scanning of brain activity

Nitric oxide inhalation reduces pain in sickle cell disease patients

Amgen to review study results of ESA in chronic renal failure patients with FDA and CRDAC

Peer partner program helps diabetic patients to manage their conditions

OrSense's NBM 200MP non-invasive Hb measurement system more accurate than invasive POC devices

NBM 200 system accurately measures hemoglobin level

Pfizer announces tasocitinib Phase 2 data for plaque psoriasis

Merck's boceprevir Phase III studies for HCV to be presented at 61st AASLD

NIH funds $1.5M for research into prediction of stroke risk in pediatric patients with sickle cell disease

sanofi-aventis announces top-line results from lixisenatide Phase III GETGOAL-L-ASIA trial for Type-2 Diabetes

XOMA completes patient enrollment in XOMA 052 Phase 2a trial

Revolutionizing Life Science: An Interview with SCIEX on ASMS, the SCIEX 7500+ System, and AI-Driven Quantitation

From Discovery Biology to ELRIG Chair

Breathing New Life into Diagnostics: Plasmion's SICRIT Technology

Latest News